Go Pro
NASDAQ:ETHZ

Flag Ship Acquisition Q2 2025 Earnings Report

Flag Ship Acquisition logo
$5.25 +0.09 (+1.74%)
As of 08/3/2026

Flag Ship Acquisition EPS Results

Actual EPS
-$3.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Flag Ship Acquisition Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Flag Ship Acquisition Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Flag Ship Acquisition Earnings Headlines

Flag Ship Acquisition (NASDAQ:ETHZ) Trading Down 3.9% - What's Next?
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing.tc pixel
See More Flag Ship Acquisition Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Flag Ship Acquisition? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Flag Ship Acquisition and other key companies, straight to your email.

About Flag Ship Acquisition

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

View Flag Ship Acquisition Profile